Beta-blockers after myocardial infarction: Are they useful to all patients? And how long should be the beta-blocker therapy?

Submitted: May 27, 2018
Accepted: May 28, 2018
Published: June 7, 2018
Accepted: May 28, 2018
Abstract Views: 3269
PDF: 649
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- Kenan Yalta, Ugur Ozkan, Tülin Yalta, Ertan Yetkin, Cardiac myxoma as a potential trigger of takotsubo cardiomyopathy: A brief review on mechanistic and clinical perspectives , Monaldi Archives for Chest Disease: Vol. 92 No. 1 (2022)
- Vaishali Verma, Sachin Sondhi, Rajesh Sharma, Kunal Mahajan, COVID-19 associated viral myocarditis: does it exist? , Monaldi Archives for Chest Disease: Vol. 90 No. 4 (2020)
You may also start an advanced similarity search for this article.